FDA to rule on Tysabri by end of March

Executives for Biogen Idec said Tuesday that they expect the U.S. Food and Drug Administration to make a decision by the end of March to clear the market return of the company's recalled drug, Tysabri. In a presentation before investors at the annual J.P. Morgan Healthcare Conference, Biogen executives said that the FDA is scheduled to rule by March's end on whether to approve new labeling for Tysabri that would warn the drug has been linked to an extremely rare but deadly brain disease called PML.READ MORE